share_log

Exicure | 8-K: Current report

Exicure | 8-K: Current report

Exicure | 8-K:重大事件
美股sec公告 ·  04/22 16:23
Moomoo AI 已提取核心訊息
On April 17, 2024, Exicure, Inc., a biotechnology company, received a delinquency notification from the Nasdaq Stock Market for not filing its annual report on Form 10-K for the year ended December 31, 2023. This failure to file has resulted in non-compliance with Nasdaq Listing Rule 5250(c)(1), which mandates timely submission of periodic financial reports to the SEC. The company had previously been granted an extension until May 20, 2024, to file its delinquent third quarter Form 10-Q and now must also file the overdue Form 10-K by the same date to regain compliance. Exicure's management is actively working to complete the Form 10-K and plans to submit it as soon as possible. The company, which has suspended its clinical and development activities, is currently exploring strategic alternatives to enhance stockholder value.
On April 17, 2024, Exicure, Inc., a biotechnology company, received a delinquency notification from the Nasdaq Stock Market for not filing its annual report on Form 10-K for the year ended December 31, 2023. This failure to file has resulted in non-compliance with Nasdaq Listing Rule 5250(c)(1), which mandates timely submission of periodic financial reports to the SEC. The company had previously been granted an extension until May 20, 2024, to file its delinquent third quarter Form 10-Q and now must also file the overdue Form 10-K by the same date to regain compliance. Exicure's management is actively working to complete the Form 10-K and plans to submit it as soon as possible. The company, which has suspended its clinical and development activities, is currently exploring strategic alternatives to enhance stockholder value.
2024年4月17日,生物技術公司Exicure, Inc. 因未提交截至2023年12月31日的10-K表年度報告而收到納斯達克股票市場的拖欠通知。未能申報導致不遵守納斯達克上市規則5250(c)(1),該規則要求及時向美國證券交易委員會提交定期財務報告。該公司此前曾獲准將拖欠的第三季度10-Q表延長至2024年5月20日,現在還必須在同日之前提交逾期的10-K表才能恢復合規。Exicure的管理層正在積極努力完成10-K表格,並計劃儘快提交。該公司已暫停臨床和開發活動,目前正在探索提高股東價值的戰略替代方案。
2024年4月17日,生物技術公司Exicure, Inc. 因未提交截至2023年12月31日的10-K表年度報告而收到納斯達克股票市場的拖欠通知。未能申報導致不遵守納斯達克上市規則5250(c)(1),該規則要求及時向美國證券交易委員會提交定期財務報告。該公司此前曾獲准將拖欠的第三季度10-Q表延長至2024年5月20日,現在還必須在同日之前提交逾期的10-K表才能恢復合規。Exicure的管理層正在積極努力完成10-K表格,並計劃儘快提交。該公司已暫停臨床和開發活動,目前正在探索提高股東價值的戰略替代方案。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息